CD27

Revision as of 04:42, 27 October 2017 by en>KolbertBot (Bot: HTTP→HTTPS (v470))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

CD27 is a member of the tumor necrosis factor receptor superfamily. It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule.

Function

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-κB and MAPK8/JNK. Adaptor proteins TRAF2 and TRAF5 have been shown to mediate the signaling process of this receptor. CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor.[1]

Clinical significance

As a drug target

Varlilumab is an antibody that binds to CD27 and is an experimental cancer treatment.

Interactions

CD27 has been shown to interact with SIVA1,[2] TRAF2[3][4] and TRAF3.[3][4]

References

  1. "Entrez Gene: CD27 CD27 molecule".
  2. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, Schlossman SF (Jun 1997). "CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (12): 6346–51. doi:10.1073/pnas.94.12.6346. PMC 21052. PMID 9177220.
  3. 3.0 3.1 Yamamoto H, Kishimoto T, Minamoto S (Nov 1998). "NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27". Journal of Immunology. 161 (9): 4753–9. PMID 9794406.
  4. 4.0 4.1 Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, Morimoto C, Ware CF, Malinin NL, Wallach D, Yagita H, Okumura K (May 1998). "CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase". The Journal of Biological Chemistry. 273 (21): 13353–8. doi:10.1074/jbc.273.21.13353. PMID 9582383.

Further reading

  • Lens SM, de Jong R, Hintzen RQ, Koopman G, van Lier RA, van Oers RH (Jun 1995). "CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth". Leukemia & Lymphoma. 18 (1–2): 51–9. doi:10.3109/10428199509064922. PMID 8580829.
  • Agematsu K (Apr 2000). "Memory B cells and CD27". Histology and Histopathology. 15 (2): 573–6. PMID 10809378.
  • van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F (Dec 2002). "Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue". Trends in Immunology. 23 (12): 586–91. doi:10.1016/S1471-4906(02)02326-8. PMID 12464570.
  • Dörner T, Lipsky PE (2005). "Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus". Lupus. 13 (5): 283–9. doi:10.1191/0961203304lu1014oa. PMID 15230280.

External links